Gliomas are aggressive brain tumors that affect children. Current treatment of high-grade glioma, most often involving surgery, radiation, and cytotoxic chemotherapy, only extend median survival of affected children to14 months, and results in significant morbidity. Low-grade glioma, that cannot be completely resected aretreated with radiation, typically after failure of chemotherapy approaches, with significant resulting neuro-cognitive and developmental risks. This project addresses a specific oncogene alteration, BRAFV600E occurring in as many as 14% of pediatric high-grade glioma. For certain subtypes of pediatric glioma thefrequency of BRAFV600E is much higher (66% in pleomorphic xanthoastrocytoma). Inhibitors that specifically target BRAFV600E have been developed and have shown remarkable efficacy against melanomas that harborthis mutation. One such inhibitor, vemurafenib, has now been FDA-approved for melanoma, and is underinvestigation for treating a number of other BRAFV600E malignancies. We have shown that BRAFV600E inhibitor treatment significanfiy extends survival of intracranial BRAFV600E glioma-bearing animals. We have also noted the activation of tumor feedback mechanisms may limit drug efficacy, suggesting that combination therapies targeting these mechanisms may further improve the response of BRAFV600E glioma to BRAF inhibitor therapy. Our preliminary studies have highlighted three specific and targetable activities that might be exploitable for this purpose. First, we have observed that CDKN2A inactivation and resultant increased CDK4/6 signaling occurs in the majority of BRAFV600E high grade glioma, and that concurrent treatment with CDK4/6 and BRAFV600E inhibitors provides additional survival benefit to animals bearing BRAFV600E and CDKN2A deficient tumors. Second, we observed that the reactivation of ERK signaling following BRAF inhibitor monotherapy is prevented by addition of a MEK inhibitor, which also increases anti-proliferative effect and survival for animais with intracranial BRAFV600E glioma. Finally, we have observed that BRAF-targeted treatment of BRAFV600E glioma results in EGFR feedback activation, suggesting that BRAF + EGFR combination therapy may augment the anti-tumor effect of BRAF monotherapy. Although these combination strategies appear to enhance BRAF inhibitor efficacy we do not fully understand the mechanistic basis for their actions, which of these combination approaches may be the most effective alone or combined with radiotherapy, or if BRAF inhibitors alone or in combination are safe in the pediatric population. These issues will be addressed in association with the proposed research that follows.

Public Health Relevance

This is a highly translational project that will further investigate and see to the clinical testing of a targeted therapeutic treatment of children with a specific, genetically-defined type of glioma. Other than surgery and radiation, there are currentiy no effective treatments for glioma in children, and the effective treatments only provide short-term relief from the cancer, while substantially contributing to patient morbidity. The research proposed here will see to the rigorous preclinical and clinical testing of novel treatments for this cancer patient population, and that hold substantial promise for improving outcomes for children with glioma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Andersson, Ulrika; Wibom, Carl; Cederquist, Kristina et al. (2014) Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro Oncol 16:1333-40
Krishnamachari, Bhuma; Il'yasova, Dora; Scheurer, Michael E et al. (2014) A pooled multisite analysis of the effects of female reproductive hormones on glioma risk. Cancer Causes Control 25:1007-13
Walsh, Kyle M; Codd, Veryan; Smirnov, Ivan V et al. (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731-5
Sandstrom, Richard S; Foret, Michael R; Grow, Douglas A et al. (2014) Epigenetic regulation by chromatin activation mark H3K4me3 in primate progenitor cells within adult neurogenic niche. Sci Rep 4:5371
Davies, Jason M; Robinson, Aaron E; Cowdrey, Cynthia et al. (2014) Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. J Neurosurg 120:331-6
Lupo, Janine M; Nelson, Sarah J (2014) Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma. Semin Radiat Oncol 24:248-58
Ostrom, Quinn T; Bauchet, Luc; Davis, Faith G et al. (2014) The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 16:896-913
Johnson, Brett E; Mazor, Tali; Hong, Chibo et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-93
Lee, Seung-Tae; Bracci, Paige; Zhou, Mi et al. (2014) Interaction of allergy history and antibodies to specific varicella-zoster virus proteins on glioma risk. Int J Cancer 134:2199-210
Ohba, Shigeo; Mukherjee, Joydeep; See, Wendy L et al. (2014) Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res 74:4836-44

Showing the most recent 10 out of 201 publications